Our Science


Cancer cells cunningly evade the immune system using many different mechanisms. We believe that only when the full potential of the human immune system is unleashed, tumors can be effectively treated or even cured. One of our therapeutic approaches is to boost both the innate and adaptive immunity with monoclonal antibodies (mAbs) and bispecific antibodies. We are also interrogating non-immune pathways that may play key roles in the tumor microenvironment for their potential in developing novel therapeutics.

Clinical Trials

  • PT199 is in a Phase 1 clinical trial for NSCLC and PDAC (the MORNINGSTAR study; ClinicalTrials.gov ID: NCT05431270).
  • PT886 is in a Phase 1 clinical trial for metastatic/advanced gastric, gastroesophageal junction and pancreatic adenocarcinoma (the TWINPEAK study; ClinicalTrials.gov ID: NCT05482893).
  • PT217 is in a Phase 1 clinical trial for advanced refractory cancers expressing DLL3 (the SKYBRIDGE study; ClinicalTrials.gov ID: NCT05652686).

Expanded Access Policy

Read more about the Expanded Access Policy.